Chen N Q, Davis A T, Canbulat E C, Liu Y X, Goueli S, McKenzie B A, Eccleston E D, Ahmed K, Holtzman J L
Medical and Research Services, Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, USA.
Biochemistry. 1996 Jun 25;35(25):8299-306. doi: 10.1021/bi960296e.
We have extensively purified three of the hepatic microsomal intralumenal Ca2+-binding proteins, CBP1, CBP2, and CBP3, which were originally described by Van et al. [(1989) J. Biol. Chem. 264, 17494-17501]. These apparently homogeneous preparations showed only single 45Ca2+ binding bands. On the basis of the peptide sequence, CBP2 was found to be highly homologous with the previously described protein ERp72. Similarly, CBP3 was identical to calreticulin and CBP1 had some homology to calmodulin. Contrary to the report of Van et al. (1989), we found that CBP2 had little thiol:protein disulfide oxidoreductase activity. Of the three purified preparations, only CBP2 exhibited apparent intrinsic protein kinase activity. This activity was found to be due to contamination of the CBP2 preparation by an extremely low concentration of tightly bound casein kinase 2 (CK2). In line with this observation, the phosphorylation was inhibited by heparin, removed by antibody to CK2, and stimulated by spermine. Furthermore, CBP2 was readily phosphorylated in vitro by added CK2 but only slowly phosphorylated by several other protein kinases. Thus, the persistence of CK2 in a highly purified preparation of CBP2 along with several other lines of evidence presented in this study might suggest that the protein CBP2 is a physiologically relevant substrate for CK2. Furthermore, these data suggest that CK2 might be localized in the lumen of the endoplasmic reticulum and that the phosphorylation of CBP2 in the lumen may play a role in the chaperone activity attributed to this protein.
我们已经对三种肝微粒体腔内钙离子结合蛋白CBP1、CBP2和CBP3进行了广泛纯化,它们最初由Van等人描述[(1989)《生物化学杂志》264, 17494 - 17501]。这些看似纯一的制剂仅显示单一的45Ca2+结合带。根据肽序列,发现CBP2与先前描述的蛋白ERp72高度同源。同样,CBP3与钙网蛋白相同,CBP1与钙调蛋白有一些同源性。与Van等人(1989)的报道相反,我们发现CBP2几乎没有巯基:蛋白质二硫键氧化还原酶活性。在这三种纯化制剂中,只有CBP2表现出明显的内在蛋白激酶活性。发现这种活性是由于CBP2制剂被极低浓度的紧密结合的酪蛋白激酶2(CK2)污染所致。与此观察结果一致,磷酸化被肝素抑制,被CK2抗体去除,并被精胺刺激。此外,CBP2在体外很容易被添加的CK2磷酸化,但仅被其他几种蛋白激酶缓慢磷酸化。因此,CK2在高度纯化的CBP2制剂中的持续存在以及本研究中呈现的其他几条证据可能表明蛋白CBP2是CK2的生理相关底物。此外,这些数据表明CK2可能定位于内质网腔中,并且腔内CBP2的磷酸化可能在归因于该蛋白的伴侣活性中起作用。